Kornimate/medical-research-clean huggingface dataset:
pet/mri, 18f-fdg pet/ct and whole body mri in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia

Conditions: Acute Myeloid Leukemia; Acute Promyelocytic Leukemia With PML-RARA

Summary: this pilot phase i trial studies how well positron emission tomography (pet)/magnetic resonance imaging (mri), fludeoxyglucose f-18 (18f-fdg) pet/computed tomography (ct), and whole body mri work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. extramedullary myeloid leukemia is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations. diagnostic procedures, such as pet/mri, 18f-fdg pet/ct and whole body mri, may help find and diagnose extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia.

primary objective: i. to estimate the incidence of extramedullary myeloid leukemia (eml) in patients with newly diagnosed acute myeloid leukemia (aml), including acute promyelocytic leukemia (apl), by imaging criteria using pet/mr (magnetic resonance), whole body mr, and pet/ct. secondary objectives: i. to qualitatively and quantitatively assess pet/mr and pet/cr that will be performed with and without fiducial markers, and to correlate these findings with clinical outcomes of treatment response, relapse, and patterns of relapse. ii. correlate findings of eml as in the primary objectives with clinical outcomes of treatment response, relapse, and patterns of relapse including location of relapse compared to site of eml. outline: patients receive gadolinium intravenously (iv) and undergo whole body pet/mri comprising diffusion weighted imaging and 3-dimentional (3d) fast spoiled gradient echo dual echo (fspgr-de) with and without fiducial markers. patients then undergo 18f-fdg pet/ct before start treatment for acute myeloid leukemia. after completion of study, patients are followed up periodically.

Eligibility criteria:
inclusion criteria: * patients with newly diagnosed aml * non-english speaking subjects will be included. verbal translation preparative sheet (vtps) short form will be utilized in consenting non-english speaking subjects. exclusion criteria: * patients with contraindications to mr * patients with a known allergy to mr contrast agents * uncontrollable claustrophobia * recipients of more than minimal anti-leukemia treatment, with minimal treatment defined as: leukapheresis, hydroxyurea, or cytarabine more than 1 g per square meter. * patients with secondary or relapsed aml or apl should be excluded. * patients with known extramedullary leukemia * positive pregnancy test in a female of childbearing potential * younger than 18 years * greater than 400 pounds in weight * patients with uncontrolled diabetes * cognitive impaired adults or prisoners will be excluded * estimated glomerular filtration rate (egfr \<30) will be excluded
influence of umbilical cord clamping time in the newborn

Conditions: Anemia Neonatal; Polycythemia Secondary; Hyperbilirubinemia, Neonatal

Summary: this study compares two umbilical cord clamping times; the early one, up to a minute (ecc) and the late or delayed one, when the cord stop beating (dcc). the additional blood volume delivered to the newborn from the placenta - placental transference - by delaying umbilical cord ligation, increases the contribution of neonatal iron with increased iron stores in the infant, without increasing neonatal morbidity.

it is an intervention study without drugs administration with a longitudinal, prospective comparison and correlational design. patients are recruited by simple random sampling to one of the two intervention groups: group 1-ecc: early clamping of the umbilical cord (before the first minute of life). group 2-dcc: delayed clamping of the umbilical cord (when it stops beating).

Eligibility criteria:
inclusion criteria: - neonates with a gestational age of 35 to 42 weeks and born through normal vaginal delivery. exclusion criteria: * monochorionic multiples * incarcerated mothers * placenta previa * concern for abruptions * rh sensitization * hydrops * congenital anomalies * the obstetrician declining to perform the intervention

Keywords: umbilical cord clamping anemia neonatal iron metabolism disorders
injectable platelet rich fibrin post tonsillectomy

Conditions: IPRF Post Tonsillectomy

Summary: to evaluate the effect of injectable prf on healing, hemostasis and pain post tonsillectomy

tonsillectomy is the most common surgical procedure performed by otolaryngologists with or without adenoidectomy. \[1\] the most important complication of tonsillectomy is post-tonsillectomy hemorrhage with potential morbidity and death. \[2\] also, severe pain and wound healing remain major problems that affect patients profoundly after surgery causing a lot of time to return to a regular diet and normal activity. \[3\] pharmacological drugs are used to control post-tonsillectomy pain but with challenges like insufficiency to control pain, the presence of contraindications, and the presence of side effects as the antiplatelet effects of nsaids lead to increased rates of postoperative hemorrhage.\[4\] growth factors and other mediators released by activated platelets play an important role in tissue regeneration and revascularization. platelet concentrates, therefore, represent a promising therapeutic tool for tissue regeneration. in recent years, the effects of platelet-rich fibrin (prf) on tissue healing have been addressed in many surgical branches, especially for dental implant surgery and plastic surgery.\[5\] injectable platelet-rich fibrin (iprf) is a recently developed leukocyte-enriched platelet concentrate, which could better assist tissue regeneration and wound healing phenomena. although initially in a liquid phase, iprf forms a dynamic fibrin gel embedding platelets, leukocytes, type 1 collagen (col1), osteocalcin (oc), growth factors, and providing a slow release of growth factors. \[6-10\]

Eligibility criteria:
inclusion criteria: - any patient indicated for tonsillectomy who will undergo either tonsillectomy alone or adenotonsillectomy exclusion criteria: 1. children who expected to be unreliable in expressing pain due to behavioural pattern or disorder, developmental delayed, age less than 5yrs 2. residence outside the city or patient unable to come for follow-up. 3. children who have high anaesthetic risk or uncontrolled medical illness. 4. bleeding diathesis. 5. acute infection. 6. unilateral tonsillectomy. 7. hemoglobin level\<10mg/dl 8. positive viral markers
comparison of stabilization exercises and pelvic floor muscle training in women with stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: the aim of the study was to compare the effects of stabilization exercises and pelvic floor muscle training in women with stress urinary incontinence.

stress urinary incontinence is involuntary urinary incontinence with increased intraabdominal pressure. different exercise approaches such as pelvic floor exercises and stabilization exercises are used in these patients. there is a need for studies comparing the effects of these exercises.

Eligibility criteria:
inclusion criteria: * women between the ages of 18-65 who have symptoms of stress or stress-dominant mixed urinary incontinence, who volunteered to participate in the study exclusion criteria: * those who are pregnant, have communication and cooperation problems, have a concomitant neurological or rheumatological disease, have a history of surgery involving the abdominal and pelvic regions in the last year, have undergone spine surgery, those diagnosed with pure urge urinary incontinence or mixed type incontinence, those with advanced pelvic organ prolapse, those with a spinal deformity (such as scoliosis), the presence of orthopedic problems in the lower extremities (such as lower extremity shortness, presence of deformity etc.) and vestibular system disorder
colvera for detection of disease recurrence

Conditions: Colorectal Adenocarcinoma

Summary: to compare the sensitivity and specificity estimates of colvera with that of a commercially available cea test for detection of recurrent disease in crc subjects who are undergoing surveillance for recurrence.

this is an observational, prospective comparison study, where blood is collected for assay of methylated bcat1 and ikzf1 dna and cea, from subjects who have undergone curative treatment for primary crc of stages ii and iii (ajcc) and who are in remission and scheduled for follow-up radiological imaging as part of their surveillance program for recurrence. participation is for one visit only as part of each subject's surveillance-monitoring schedule. two k2-edta blood tubes and two paxgene™ tubes will be collected any evidence of methylated bcat1 and/or ikzf1 dna in blood represents a colvera "positive" result. cea levels of 5ug/l or higher will represent a "positive" result. sensitivity and specificity of the colvera and cea test will be estimated and compared in a paired fashion in each case where recurrence status has been investigated and determined by the site clinical management team. blood testing shall be performed and analyzed by qualified staff blinded to clinical status. this is a cross-sectional observational non-significant risk study, and test results will not be used for clinical management, i.e. there will be no interventions in subjects consenting to participate in this research study.

Eligibility criteria:
inclusion criteria: 1. subject is 18 years or older, and capable and willing to provide informed consent. 2. subject has undergone curative treatment for primary crc of stages ii and iii (ajcc). 3. subject has no clinical evidence of disease (ned) (after initial treatment) 4. subject has concluded course of initial treatment for primary crc (i.e. end of surgery, chemotherapy and/or radiotherapy) 5. subject is willing/able to provide a blood sample exclusion criteria: 1. subject has evidence of residual disease. 2. subject has other organ cancer at the time of recruitment. 3. subject has prior history of recurrent crc. 4. subject has concurrent serious non-neoplastic illness that makes enrollment impractical or clinically inappropriate. 5. subject is receiving chemo- or radiotherapy at the time of blood collection, or between blood collection and radiological imaging.
the relationship of developing metabolic acidosis with antiepleptic drugs in craniotomy operations

Conditions: Metabolic Acidosis; Antiepileptic Drugs; Craniotomy; Anesthesia Management

Summary: the relationship of developing metabolic acidosis with antiepleptic drugs in craniotomy operations

metabolic acidosis is a life-threatening complication in the perioperative, intraoperative and postoperative period. it can cause decreased cardiac output, electrolyte imbalance, surgical bleeding and neurological complications, even coma and death in surgical patients. topiramate and zonisamide are sulfonamide derivative compounds used in the treatment of epilepsy. it has been shown in studies that both drugs have a strong inhibition of carbonic anhydrase enzyme. recent case reports suggest that both drugs may cause metabolic acidosis by lowering serum bicarbonate levels in some patients. aim in this study is to determine the relationship between preoperative, intraoperative and postoperative metabolic acidosis and to emphasize the importance of anesthesia management in patients who have undergone craniotomy and use antiepileptic drugs.

Eligibility criteria:
inclusion criteria: * patients undergoing intracranial surgery with craniotomy and using antiepileptic drugs * asa i-iii * patients undergoing elective surgery exclusion criteria: * patients with a surgical procedure time of more than 5 hours * patients who received more than 2 units of blood transfusion during the operation * patients taking other drugs that can cause metabolic acidosis * patients with diabetes mellitus, diabetes insipidus, hepatic or renal disease

Keywords: antiepileptic drugs metabolic acidosis anesthesia management craniotomy
relations between myotonia and fitness

Conditions: Congenital Myotonia

Summary: investigators aimed to investigate whether training can increase fitness levels in patients with myotonia, and thereby reduce the symptom of myotonia.

investigators aimed to investigate whether a 10-week bicycle exercise program can increase fitness levels in patients with myotonia, and thereby reduce the symptom of myotonia in everyday life. the effect on myotonia is assessed by a standardized myotonia scale with six statements concerning self-rated myotonia, and a number of performance tests that objectively describes the degree of myotonia. the effect of the training program is assessed by an incremental test, measuring maximal oxygen uptake, maximal heart rate and maximal workload. the muscle enzyme creatine kinase (ck) is measured in plasma to follow muscle injury and safety during the training.

Eligibility criteria:
inclusion criteria: * diagnosed with either myotonia congenita or paramyotonia congenita. * patients who have symptoms of myotonia while they are walking stairs. exclusion criteria: * pregnant or breastfeeding women. * physical or mental condition, which prevent participating in the study protocol or which could influence the results. * participating in other studies, which could influence the results.

Keywords: congenital myotonia myotonia congenita thomsons disease becker type training exercise
follow-up of arthrosurface hemicap implants

Conditions: Orthopedic Disorder

Summary: follow-up of arthrosurface hemicap shoulder implants.

in summary, the investigators would like to contact all patients who have had hemicap implants done at ccf with at least 2 years of follow-up after their procedure. the investigators will use electronic or written means to alert the patients that they will be contacted by our team to discuss their surgery and any related issues. once the appropriate consent is obtained, the investigators will use a brief telephone interview to ask the patients several questions regarding any re-operations or complications the patients have had since the index procedure.

Eligibility criteria:
inclusion criteria: -patients who had arthrosurface (franlin, ma) hemicap implants placed into their shoulders at the cleveland clinic exclusion criteria: * anyone who has not had arthrosurface (franlin, ma) heicap implants placed into their shoulders at the cleveland clinic
safety and efficacy of thiscart7 in patients with refractory or relapsed t cell malignancies

Conditions: T-Acute Lymphoblastic Leukemia; T-cell Non-Hodgkin Lymphoma; T-cell Acute Lymphoblastic Lymphoma

Summary: this is a single dose escalation study to evaluate the safety and clinical activity of thiscart7(allogeneic car-t targeting cd7) in patients with refractory or relapsed cd7 positive t cell malignancies.

this is a single-center, nonrandomized, open-label, dose-escalation study to evaluate the safety and clinical activity of thiscart7 in patients with refractory or relapsed cd7 positive t cell malignancies, such as t-cell acute lymphoblastic leukemia, t-cell acute lymphoblastic lymphoma and t-cell non-hodgkin lymphoma. the dose range is 0.5-6 x 10\^6 cells per kg body weight.

Eligibility criteria:
inclusion criteria: 1. diagnosed with relapsed and refractory cd7 + t cell hematologic malignancies (including, but not limited to, t-cell leukemia, extranodal nk/ t-cell lymphoma nasal, peripheral t-cell lymphoma, enteropathy associated t-cell lymphoma and anaplastic t-cell lymphoma, etc.); 2. no alternative treatment options deemed by investigator; 3. measurable or detectble disease at time of enrollment; 4. age 18-70 years old, no gender and race limited; 5. eastern cooperative oncology group (ecog) performance status of ≤2; 6. cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by an echocardiogram (echo); 7. estimated life expectancy \> 12 weeks deemed by investigator; 8. serum creatinine ≤ 1.5 upper limit of normal (uln); 9. serum alt/ ast ≤ 5 upper limit of normal (uln); 10. signed informed consent form (icf). exclusion criteria: 1. women in pregnancy or lactation; 2. uncontrolled infection; 3. active hepatitis b virus or hepatitis c virus infection; 4. concurrent use of corticosteroids or other immunosuppressant medications for chronic disease; 5. prior treatment with an allogeneic stem cell transplant within 100 days; 6. grade 2-4 active graft versus host disease; 7. history of hiv infection; 8. with central nervous system involvement; 9. patients combine with other disease cause neutrophil count (anc) \< 750/ul or plt\< 50,000/ul.
study of ono-1078 in patients with chronic sinusitis

Conditions: Chronic Sinusitis

Summary: to determine the efficacy and safety of ono-1078 in patients with chronic sinusitis in a double-blind, randomized, placebo-controlled, parallel group, multi-center study


Eligibility criteria:
inclusion criteria: * chronic sinusitis exclusion criteria: * acute sinusitis * chronic sinusitis with acute exacerbation

Keywords: ono-1078 chronic sinusitis
comparing children's books to brochures for safe sleep and infant reading education during prenatal care

Conditions: Sudden Unexplained Infant Death; Child Rearing; Literacy

Summary: the aim of this randomized trial is to compare a specially designed children's book to brochures for safe sleep education via clinical providers at a third trimester prenatal obstetric visit. mothers in the control group will receive a specially designed children's book regarding the importance of reading with their infant at this visit, compared to brochures. knowledge of safe sleep and home literacy orientation will be assessed at baseline prenatally, and their first postpartum obstetric visit.

this study is a randomized controlled trial (rct) involving 2 groups of pregnant women from low-socioeconomic status (ses) backgrounds at-risk for adverse cognitive and health outcomes for their infant. mothers will be randomly assigned to intervention and control groups during a third-trimester prenatal visit at a hospital-affiliated obstetric clinic, via convenience sampling. mothers in the intervention group will receive education on american academy of pediatrics (aap) safe sleep recommendations using a specially-designed children's book (sleep baby, safe and snug), while those in the control group will receive this guidance via a brochure endorsed by the aap. in a "mirror" design, mothers in the control group will receive guidance on reading with their infant using a specially designed children's book (read baby, every day), and mothers in the intervention group will receive guidance on reading with their infant using a brochure created and endorsed by the aap. clinical research coordinators (crcs) will obtain consent and collect data at two time points: 1) a 3rd trimester prenatal visit (approximately 36-38 weeks estimated gestational age; baseline), and 2) at the first, regularly scheduled postpartum visit (4-6 weeks after delivery for an uncomplicated vaginal delivery, and 2 weeks for cesarean section). data will be collected in 4 categories, which will be compared between groups: 1) demographics, 2) maternal knowledge of aap safe sleep recommendations, 3) maternal attitudes about reading with infants, 4) maternal impression of the printed educational materials provided, and 4) clinician impression of the feasibility and usefulness of the printed materials provided for obstetric prenatal care. educational materials will be shared with mothers by obstetric providers (obstetric attending physicians and residents) during this visit, who will be provided with a brief summary of content and to conduct the visit as they see fit. mothers will be blinded to the aims of the study, other than that it is to "share information about safe sleep and reading with your baby."

Eligibility criteria:
inclusion criteria: 1. confirmed viable pregnancy, with estimated gestational age (ega) of at least 36 weeks at the baseline/enrollment prenatal visit, 2. maternal age at least 16 years old, 3. comfort speaking english during their visit and reviewing/comprehending study materials without a translator. exclusion criteria: non-meeting the above.
asan medical center myocardial infarction registry

Conditions: Myocardial Infarction, Acute; Coronary Stenosis

Summary: this study evaluates long-term outcome of patients diagnosed as acute myocardial infarction and treated with medication, coronary artery bypass surgery and percutaneous coronary intervention in asan medical center, korea.

this study will collect 3000 cases retrospectively and 2000 cases prospectively.

Eligibility criteria:
inclusion criteria: * all consecutive acute myocardial infarction patients diagnosed through coronary angiography

Keywords: acute myocardial infarction myocardial infarction
within-subject variability of insulin detemir in healthy volunteers

Conditions: Diabetes; Healthy

Summary: this trial is conducted in europe. the aim of this trial is to compare the within-subject variability of insulin detemir to that of another basal insulin analogue, insulin glargine in healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy japanese men or women * holding a japanese pass-port and japanese-born parents * considered generally healthy upon completion of medical history and physical examination as judged by the investigator * body mass index (bmi) between 18 and 30 kg/m\^2, incl. * fasting blood glucose maximum 6 mmol/l exclusion criteria: * clinically significant abnormal haematology or biochemistry screening tests, as judged by the investigator * any serious systemic infectious disease that occurred during the four weeks prior to the first dose of the trial product, as judged by the investigator * subject with history of alcohol or drug dependence
immunointervention with calcitriol in new-onset type 1 diabetes

Conditions: Type 1 Diabetes

Summary: this is a randomized, two-arm, placebo-controlled phase-2 trial to determine whether the daily intake of 1,25-dihydroxy-vitamin d3 \[1,25(oh)2d3\], improves beta cell function in patients with recently diagnosed type 1 diabetes. the treatment consists of the daily oral administration of 0.25 µg 1,25(oh)2d3 or placebo for 9 months and an equal follow-up time without supplementation. fasting, peak and auc c-peptide concentrations during a 2-hour mixed meal tolerance test are measured at the beginning of the study, as well as at the end of the treatment and the follow-up period in month 9 and 18. the null hypothesis is that there is no difference between 1,25(oh)2d3 treated subjects and the placebo group in the auc c-peptide at month 18.


Eligibility criteria:
inclusion criteria: * new onset typ 1 diabetes (\< 6 weeks insulin therapy) * age 18-39 years * gada and/or ia-2a positive exclusion criteria: * kidney disease * pregnancy * lactating

Keywords: new-onset